Celltrion (XKRX:068270) Common Stock : ₩220,291 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Celltrion Common Stock?

Celltrion's quarterly common stock increased from Jun. 2023 (₩146,391 Mil) to Sep. 2023 (₩146,403 Mil) and increased from Sep. 2023 (₩146,403 Mil) to Dec. 2023 (₩220,291 Mil).

Celltrion's annual common stock increased from Dec. 2021 (₩137,947 Mil) to Dec. 2022 (₩140,805 Mil) and increased from Dec. 2022 (₩140,805 Mil) to Dec. 2023 (₩220,291 Mil).

Celltrion Common Stock Historical Data

The historical data trend for Celltrion's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celltrion Common Stock Chart

Celltrion Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

128,337.85

134,997.81

137,947.13

140,805.21

220,290.52

Celltrion Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															140,805.21	146,331.20	146,390.86	146,402.77	220,290.52

Celltrion Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Celltrion (XKRX:068270) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celltrion Inc (XKRX:068270) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

13-6 SongDo-Dong, Yeonsu-gu, Incheon City, KOR, 406-840

Website

http://www.celltrion.com

Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.

Celltrion (XKRX:068270) Headlines

No Headlines